Across all DME patients dosed to date, 4D-150 continues to be well tolerated with no intraocular inflammation observed at any timepoint or dose level3E10 vg/eye demonstrated strong signals of clinical...

WOBURN, Mass. , Jan. 08, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today anno...

Study did not demonstrate statistically significant improvement on primary endpoint of reduction in depressive symptoms as measured by MADRS total score compared to placebo Navacaprant showed an efficacy signal in female participants; Company plans to further analyze results Navacaprant generally

Landmark publication in leading ophthalmology research journal demonstrates the power of 4DMT’s Therapeutic Vector Evolution platform to invent potentially best-in-class customized vectors and transfo...

By participating in cutting-edge research at University of Iowa Health Care, Linda Jacobs beat cancer. Now, she is relishing time with her grandchildren, exploring new hobbies, and training a puppy.

Groundbreaking Cretostimogene Grenadenorepvec Monotherapy Data Demonstrates Sustained, Durable Complete Responses in High-Risk BCG-Unresponsive Non-Muscle Invasive Bladder Cancer – 74.5% of patients a...

SAN DIEGO, Dec. 04, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunothera...

Boyd’s 18th novel is a spy thriller about a travel writer who gets recruited by MI6.

Fresh off of raising more than €2 billion for two new funds in October, he gives his take on the biotech markets both in Europe and globally.Forbion Full

Jim Wilson said he's leaving the University of Pennsylvania to show biotechs can successfully commercialize gene therapies for rare diseases.